Vicore to host Key Opinion Leader webinar on C21 for the treatment of idiopathic pulmonary fibrosis (IPF)

Webinar on Thursday, September 30 @ 16:00 CET (10AM ET) with the medical doctors and IPF experts Prof. Toby Maher and Prof. Joanna Porter.

Gothenburg, September 22, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis (IPF), today announced it will host a key opinion leader (KOL) webinar on C21, the company's lead asset for the treatment of idiopathic pulmonary fibrosis (IPF) on Thursday, September 30, 2021 at 16:00 CET (10 AM Eastern Time).

The webinar will feature a presentation by KOLs Professor Toby Maher, M.D., Ph.D., University of Southern California, and Professor Joanna Porter, M.D., Ph.D., University College London who will discuss the current treatment landscape, unmet medical need in treating patients with IPF as well as the phase 2 study with C21 in IPF (AIR). Prof. Maher and Prof. Porter will be available to answer questions following the formal presentations.

Vicore CMO, Rohit Batta will also give a corporate overview and update on the company's activities within IPF.

To register for the webinar, please click here.

Toby Maher, M.D. is a Professor of Clinical Medicine at the Keck School of Medicine at the University of Southern California. Additionally, Prof Maher is the British Lung Foundation Chair in Respiratory Research and National Institute for Health Research (NIHR) Clinician, Scientist. He is a Professor of Interstitial Lung Disease and heads up the Fibrosis Research Group at the National Heart and Lung Institute, Imperial College, London. He is also an honorary Consultant Respiratory Physician on the Interstitial Lung Disease Unit, Royal Brompton Hospital, and is Director of the NIHR Respiratory Clinical Research Facility and Director of Respiratory Research at Royal Brompton Hospital.

His research interests include: biomarker discovery, the lung microbiome and host immune response in the pathogenesis of IPF, and clinical trials in interstitial lung disease. He has been involved in >50 trials in fibrotic lung disease from phase 1b through to phase 4 and including those assessing IPF, scleroderma, rheumatoid arthritis, and inflammatory myositis. Overall, he has recruited >1000 patients into interventional studies. He has given expert opinions to both the FDA and EMA.

 He is an associate editor for the American Journal of Respiratory and Critical Care Medicine and is on the International Advisory Board for Lancet Respiratory Medicine. He has authored over 260 papers and book chapters on pulmonary fibrosis.

Joanna Porter, M.D. is Professor of Respiratory Medicine at University College London, a Consultant in Respiratory and General Medicine at UCL Hospital, and head of the National Interstitial Lung Disease (ILD) service at UCL Hospital. In addition, she is the Medical Director of the UCL partners ILD Consortium, and the Medical Director of the Breathing Matters Charity. Professor Porter trained in Medicine at Cambridge and Oxford Universities and specialized in Respiratory Diseases (with subspecialty interest in ILD) at hospitals in London. Professor Porter heads a basic research group focused on understanding lung inflammation in health and disease. This work aligns with, and informs her clinical practice in ILD with the aim of finding better precision treatments and eventually a cure for pulmonary fibrosis. Most recently she is involved in a national UK study to investigate the effects of COVID-19 on the development and progression of lung fibrosis. Professor Porter has taken part in >50 clinical studies/trials in ILD and has published >60 papers. She is passionate about education and supporting and training the next generation of clinical academics in ILD.

C21 - a first-in-class AT2R agonist
C21 is a first-in-class, orally available, low molecular weight, angiotensin II type 2 receptor (AT2R) agonist that activates the "protective arm" of the renin-angiotensin system (RAS) leading to resolution and regeneration following tissue damage. The compound is currently in a phase 2 proof-of-concept trial in IPF and in a pivotal phase 3 trial in COVID-19. Given the therapeutic potential of AT2R agonism in additional indications with significant unmet medical needs, Vicore has intensified the efforts to develop proprietary follow-up molecules with differentiated profiles.

For further information:
Carl-Johan Dalsgaard, CEO
Tel: +46 70 975 98 63
E: [email protected] 

This information was submitted for publication on September 22, 2021 at 08.30 CET.

About Vicore Pharma Holding AB (publ)
Vicore Pharma is a rare disease pharmaceutical company focused on severe lung disease and related indications. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and COVID-19. VP02 is based on a new formulation and delivery route of thalodimide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2R agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.

The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com

Delårsrapport juli - september 2021

Göteborg, 4 november 2021 - Vicore Pharma Holding AB (publ) publicerar sin delårsrapport för tredje kvartalet 2021.


Interim report July - September 2021

Gothenburg, November 4, 2021 - Vicore Pharma Holding AB (publ) publishes the interim report for the third quarter 2021.


Vicores C21 minskar långsiktiga lungskador efter COVID-19 i ATTRACT fas 2 uppföljningsstudien

  • Resultaten visade närmare 50% minskning av uppkomna lungskador efter behandling med C21  jämfört med placebo
  • Dessa positiva fynd tillsammans med tidigare kliniska resultat1 talar för att C21 kan påskynda återhämtningen  
  • C21 utvärderas för närvarande vid en fas 3-studie i COVID-19 patienter

Göteborg,  2 november, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), ett särläkemedelsföretag som utvecklar innovativa behandlingar mot svåra lungsjukdomar, meddelar idag resultat att behandling med bolagets AT2R agonist, C21, minskar långsiktiga lungskador hos sjukhusinlagda COVID-19 patienter.


Lancets EClinicalMedicine publicerar resultat från fas 2-studie med C21 i COVID-19

  • Studien visade att C21 minskade behovet av syrgas- och respiratorbehandling, vilket indikerar en snabbare återhämtning. C21 var också säkert och väl tolererat.
  • Resultaten låg till grund för Vicores beslut att gå vidare med en fas 3-studie vilken beräknas vara klar första halvåret 2022.

Göteborg, 25 oktober, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), ett särläkemedelsföretag som utvecklar innovativa behandlingar mot svåra lungsjukdomar, meddelar idag att resultaten från fas 2-studien ATTRACT med angiotensin II typ 2 receptor agonisten C21 i COVID-19 har publicerats i EClinicalMedicine, en expertgranskad vetenskaplig tidskrift utgiven av The Lancet. Publikationen finns tillgänglig online via denna länk.


Lancet's EClinicalMedicine publishes phase 2 data on C21 in COVID-19

  • The trial showed that C21 reduced the need for supplemental oxygen and mechanical ventilation, indicating faster patient recovery. C21 was also found to be safe and well tolerated.
  • Data encouraged Vicore to move into phase 3 with readout on-track for H1 2022.

Gothenburg, October 25, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the results of the COVID-19 phase 2 trial of its angiotensin II type 2 receptor agonist C21 have been published in EClinicalMedicine, a peer reviewed clinical journal, published by The Lancet. The paper is available online via this link.


Vicore offentliggör valberedningen inför årsstämman 2022

Göteborg, 20 oktober, 2021 - Vicore Pharma Holding AB (publ) har utsett valberedningen inför årsstämman 2022. De tre största aktieägarna per den 31 augusti 2021 har erbjudits att utse en ledamot till valberedningen vardera, i enlighet med beslutet som togs på årsstämman den 11 maj 2021.


Vicore håller webbinarium om C21 för behandling av idiopatisk lungfibros (IPF)

Webbinariet hålls torsdagen den 30 september @16:00 CET (10:00 am EST) med läkarna och IPF-experterna, Prof. Toby Maher och Prof. Joanna Porter.

Göteborg, 22 september, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), ett särläkemedelsbolag som utvecklar innovativa läkemedel mot svåra lungsjukdomar meddelar idag att bolaget kommer att hålla ett webbinarium om C21, Vicores ledande läkemedelsmolekyl, för behandling av idiopatisk lungfibros (IPF), torsdagen den 30 september kl. 16:00 CET (10:00 am EST).


Vicore to host Key Opinion Leader webinar on C21 for the treatment of idiopathic pulmonary fibrosis (IPF)

Webinar on Thursday, September 30 @ 16:00 CET (10AM ET) with the medical doctors and IPF experts Prof. Toby Maher and Prof. Joanna Porter.

Gothenburg, September 22, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis (IPF), today announced it will host a key opinion leader (KOL) webinar on C21, the company's lead asset for the treatment of idiopathic pulmonary fibrosis (IPF) on Thursday, September 30, 2021 at 16:00 CET (10 AM Eastern Time).


Vicore erhåller SARS coronavirus-patent för C21 i USA

Göteborg, 22 september, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), ett särläkemedelsföretag som utvecklar innovativa behandlingar mot svåra lungsjukdomar, meddelar idag att US Patent and Trademark Office (USPTO) har beviljat patentet US11,123,329 som omfattar användningen av C21 för att behandla infektioner orsakade av Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), inklusive SARS-CoV-2.


Vicore behandlar första COVID-19 patienterna i den globala fas 3-studien ATTRACT-3

Göteborg, 17 september, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), ett särläkemedelsbolag som utvecklar innovativa läkemedel mot svåra lungsjukdomar meddelar idag att de första patienterna i bolagets globala fas 3-studie med C21 i COVID-19 (ATTRACT-3) doserats.

  • Tidigare rapporterade positiva resultat från fas 2-studien ger starkt stöd för fortsatt utvärdering av Vicores AT2 receptor agonist C21 i COVID-19
  • Den pivotala fas 3-studien är nu godkänd i USA, Ukraina, Sydafrika, Brasilien, Tjeckien, Filippinerna och Indien med syftet att undersöka effektiviteten och säkerheten av C21 på sjukhusinlagda patienter med COVID-19

Göteborg, 17 september, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), ett särläkemedelsbolag som utvecklar innovativa läkemedel mot svåra lungsjukdomar meddelar idag att de första patienterna i bolagets globala fas 3-studie med C21 i COVID-19 (ATTRACT-3) doserats.


Vicore starts dosing of first COVID-19 patients in the global phase 3 trial ATTRACT-3

Gothenburg, September 17, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders today announces the dosing of the first patients in the company's global phase 3 trial of C21 in COVID-19 (ATTRACT-3).

  • Previously reported positive phase 2 trial results strongly support further evaluation of the Vicore AT2 receptor agonist C21 in COVID-19
  • The pivotal phase 3 trial is currently approved in the US, Ukraine, South Africa, Brazil, Czechia, Philippines and India to investigate the efficacy and safety of C21 in hospitalized patients with COVID-19

Vicore stärker sin ledningsgrupp

Göteborg, 27 augusti, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), ett särläkemedelsbolag som utvecklar innovativa läkemedel för fibrotiska lungsjukdomar som idiopatisk lungfibros (IPF), meddelar idag att bolagets ledningsgrupp stärks med tre seniora rekryteringar när bolagets forsknings- och utvecklingsaktiviteter närmar sig viktiga kommersiella milstolpar.


Delårsrapport april - juni 2021

Göteborg, 26 augusti 2021 - Vicore Pharma Holding AB (publ) publicerar sin delårsrapport för andra kvartalet 2021.


Interim report April - June 2021

Gothenburg, August 26, 2021 - Vicore Pharma Holding AB (publ) publishes the interim report for the second quarter 2021.


Vicore meddelar om deltagande i investerarmöten under juni 2021

Göteborg, 15 juni, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), som ett särläkemedelsbolag som utvecklar innovativa läkemedel mot fibrotiska lungsjukdomar som idiopatisk lungfibros (IPF), meddelar idag om deltagande i två investerarkonferenser under juni månad 2021.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted